AstraZeneca announces new safety data for naloxegol AstraZeneca announced the results of a Phase III long-term safety and tolerability study of the once-daily 25mg dose of naloxegol, in patients with non-cancer pain and opioid-induced constipation. Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist, which has been studied in OIC in adult patients with chronic non-cancer pain, a common condition caused by prescription opioid pain medicines. “The data from the long-term safety study further support the safety and tolerability of naloxegol, a PAMORA which could help address an unmet need for millions of patients with OIC.” said AstraZeneca.
News For AZN From The Last 14 Days
Check below for free stories on AZN the last two weeks.
Leerink's biotech/pharma analysts hold an analyst/industry conference call Biotech Analyst Kozul and Major Pharmaceuticals Analyst Fernandez provide a review of Emerging 3rd Generation Tyrosine Kinas Inhibitors (TKI) Data for Non-Small Cell Lung Cancer (NSCLC) on an Analyst/Industry conference call. Relevant companies AstraZeneca (AZN) and Clovis Oncology (CLVS) may be discussed on the Analyst/Industry conference call to be held on December 12 at 1 pm.